| 7.6 2.6 (52%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.25 |
1-year : | 10.81 |
| Resists | First : | 7.92 |
Second : | 9.25 |
| Pivot price | 5.24 |
|||
| Supports | First : | 5.12 |
Second : | 3.4 |
| MAs | MA(5) : | 5.86 |
MA(20) : | 4.87 |
| MA(100) : | 5.48  |
MA(250) : | 9.51 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 72.3 |
D(3) : | 73.1 |
| RSI | RSI(14): 73.5 |
|||
| 52-week | High : | 17.94 | Low : | 3.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AARD ] has closed above the upper band by 18.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 0.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.93 - 7.98 | 7.98 - 8.02 |
| Low: | 4.96 - 4.99 | 4.99 - 5.03 |
| Close: | 7.52 - 7.6 | 7.6 - 7.67 |
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Fri, 10 Jul 2026
[DEF 14A] Aardvark Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Thu, 02 Jul 2026
Aardvark Therapeutics, Inc. Common Stock (NASDAQ: AARD) Stock Price, News & Analysis - Kalkine
Mon, 23 Mar 2026
Aardvark Therapeutics 10-K: $0 Revenue; $(2.93) EPS - TradingView
Tue, 03 Mar 2026
Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101 - simplywall.st
Thu, 12 Feb 2026
Aardvark creates Ardia to develop psoriasis and severe skin treatments - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 16.1 (%) |
| Held by Institutions | 56.4 (%) |
| Shares Short | 912 (K) |
| Shares Short P.Month | 1,010 (K) |
| EPS | -3.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.99 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.6 % |
| Return on Equity (ttm) | -58.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -62 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -2.37 |
| PEG Ratio | 0 |
| Price to Book value | 1.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|